NCT05503979View on ClinicalTrials.gov

Elimination of Hepatitis C Virus Among Users of Substances

UnknownOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

August 15, 2023

Study Completion Date

May 15, 2024

Conditions

Hepatitis C in Substance Users

Interventions

DRUG

Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]

1 tab every 24 hrs for 12 weeks

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

OTHER

NCT05503979 - Elimination of Hepatitis C Virus Among Users of Substances | Biotech Hunter | Biotech Hunter